Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

7Total
Not Applicable (1)
P 1 (4)
P 2 (2)

Trial Status

Not Yet Recruiting3
Recruiting3
Active Not Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07493382Not ApplicableNot Yet RecruitingPrimary

Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy

NCT07454642Phase 1Recruiting

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

NCT04430738Phase 2Active Not Recruiting

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT07182149Phase 1Recruiting

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

NCT07334431Phase 1Recruiting

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

NCT06888037Phase 2Not Yet Recruiting

Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer

NCT06871527Phase 1Not Yet Recruiting

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Showing all 7 trials

Research Network

Activity Timeline